Celiac Disease - Pipeline Review
H1 2013

Celiac Disease - Pipeline Review H1 2013

Celiac Disease - Pipeline Review, H1 2013

Summary

Global Markets Direct's, 'Celiac Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Celiac Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Celiac Disease. Celiac Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Celiac Disease.
• A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Celiac Disease pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Celiac Disease.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

• Introduction
  • Global Markets Direct Report Coverage
  • Celiac Disease Overview
• Therapeutics Development
  • An Overview of Pipeline Products for Celiac Disease
  • Celiac Disease Therapeutics under Development by Companies
  • Celiac Disease Therapeutics under Investigation by Universities/Institutes
  • Mid Clinical Stage Products
  • Comparative Analysis
  • Early Clinical Stage Products
  • Comparative Analysis
  • Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Celiac Disease Therapeutics - Products under Development by Companies
  • Celiac Disease Therapeutics - Products under Investigation by Universities/Institutes
• Companies Involved in Celiac Disease Therapeutics Development
  • BioLineRx, Ltd.
  • Alba Therapeutics Corporation
  • ActogeniX NV
  • Artielle ImmunoTherapeutics, Inc.
  • Altor BioScience Corporation
  • Alvine Pharmaceuticals, Inc.
  • Avaxia Biologics, Inc.
  • Provid Pharmaceuticals, Inc.
  • FunZyme BioTechnologies S.A.
  • Celiac Disease
• Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Drug Profiles
  • Nexvax-2 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ActoBiotics For Celiac Disease - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ALT-836 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • larazotide acetate - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • RTL For Celiac Disease - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ALV-003 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Transglutaminase 2 inhibitors - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • AVX-176 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ZED-101 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • 2nd Generation Proteases - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • tTG Inhibitors - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • HLA-DQ2 Blockers - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • BL-7010 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Nexvax-3 Therapy - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Interleukin-27 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Drug Targeting DQ2/DQ8 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Celiac Disease Therapeutics - Drug Profile Updates
  • Celiac Disease Therapeutics - Dormant Products
  • Celiac Disease - Product Development Milestones
• Featured News & Press Releases
  • Sep 10, 2012: Biolinerx Announces Pre-clinical Results Demonstrating Safety Of BL-7010
  • Sep 05, 2012: Alvine Pharma's ALV003 Receives Fast Track Designation From FDA For Treatment Of Celiac Disease
  • Sep 04, 2012: ImmusanT Initiates Clinical Trials Of Nexvax2 Therapeutic Vaccine For Celiac Disease
  • May 22, 2012: Alvine Presents Phase IIa Trial Results Of ALV003 In Celiac Disease Patients At 2012 Digestive Diseases Week Meeting
  • May 01, 2012: Alba Gains Exclusive Rights To Patient Reported Outcome Questionnaire For Patients With Celiac Disease
  • Feb 21, 2012: BioLineRx Announces Publication Of Pre-Clinical Results Demonstrating Efficacy Of BL-7010 In Reducing Gluten Toxicity
  • Jan 11, 2012: Microtest Laboratories To Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine For Expected Clinical Trial
  • Oct 24, 2011: Alvine Pharmaceuticals Presents Additional Efficacy Data From Phase IIa Trial of ALV003 in Celiac Disease Patients
  • Oct 11, 2011: Alvine Pharmaceuticals Announces Positive Results From Phase IIa Trial Of ALV003 In Celiac Disease Patients
  • Sep 22, 2011: Alvine Pharmaceuticals Announces Upcoming Presentation Of Phase IIa ALV003 Data In Patients With Celiac Disease
• Appendix
• Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • R&D Progress
• Disclaimer
• List of Tables
  • Number of Products Under Development for Celiac Disease, H1 2013
  • Products under Development for Celiac Disease - Comparative Analysis, H1 2013
  • Number of Products under Development by Companies, H1 2013
  • Number of Products under Investigation by Universities/Institutes, H1 2013
  • Comparative Analysis by Mid Clinical Stage Development, H1 2013
  • Comparative Analysis by Early Clinical Stage Development, H1 2013
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
  • Products under Development by Companies, H1 2013
  • Products under Investigation by Universities/Institutes, H1 2013
  • BioLineRx, Ltd., H1 2013
  • Alba Therapeutics Corporation, H1 2013
  • ActogeniX NV, H1 2013
  • Artielle ImmunoTherapeutics, Inc., H1 2013
  • Altor BioScience Corporation, H1 2013
  • Alvine Pharmaceuticals, Inc., H1 2013
  • Avaxia Biologics, Inc., H1 2013
  • Provid Pharmaceuticals, Inc., H1 2013
  • FunZyme BioTechnologies S.A., H1 2013
  • Assessment by Monotherapy Products, H1 2013
  • Assessment by Stage and Route of Administration, H1 2013
  • Assessment by Stage and Molecule Type, H1 2013
  • Celiac Disease Therapeutics - Drug Profile Updates
  • Celiac Disease Therapeutics - Dormant Products
• List of Figures
  • Number of Products under Development for Celiac Disease, H1 2013
  • Products under Development for Celiac Disease - Comparative Analysis, H1 2013
  • Products under Development by Companies, H1 2013
  • Products under Investigation by Universities/Institutes, H1 2013
  • Mid Clinical Stage Products, H1 2013
  • Early Clinical Stage Products, H1 2013
  • Discovery and Pre-Clinical Stage Products, H1 2013
  • Assessment by Monotherapy Products, H1 2013
  • Assessment by Route of Administration, H1 2013
  • Assessment by Stage and Route of Administration, H1 2013
  • Assessment by Molecule Type, H1 2013
  • Assessment by Stage and Molecule Type, H1 2013